Proteostasis disturbance in amyotrophic lateral sclerosis
Author
dc.contributor.author
Medinas Bilches, Danilo
Author
dc.contributor.author
Valenzuela Paterakis, Vicente
Author
dc.contributor.author
Hetz Flores, Claudio
Admission date
dc.date.accessioned
2019-06-11T13:03:31Z
Available date
dc.date.available
2019-06-11T13:03:31Z
Publication date
dc.date.issued
2017
Cita de ítem
dc.identifier.citation
Human Molecular Genetics, 2017, Vol. 26, No. R2
es_ES
Identifier
dc.identifier.issn
0964-6906
Identifier
dc.identifier.other
10.1093/hmg/ddx274
Identifier
dc.identifier.uri
https://repositorio.uchile.cl/handle/2250/169850
Abstract
dc.description.abstract
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease affecting motoneurons in the brain and spinal cord leading to paralysis and death. Although the etiology of ALS remains poorly understood, abnormal protein aggregation and altered proteostasis are common features of sporadic and familial ALS forms. The proteostasis network is decomposed into different modules highly conserved across species and comprehends a collection of mechanisms related to protein synthesis, folding, trafficking, secretion and degradation that is distributed in different compartments inside the cell. Functional studies in various ALS models are revealing a complex scenario where distinct and even opposite effects in disease progression are observed depending on the targeted component of the proteostasis network. Importantly, alteration of the folding capacity of the endoplasmic reticulum (ER) is becoming a common pathological alteration in ALS, representing one of the earliest defects observed in disease models, contributing to denervation and motoneuron dysfunction. Strategies to target-specific components of the proteostasis network using small molecules and gene therapy are under development, and promise interesting avenues for future interventions to delay or stop ALS progression
es_ES
Patrocinador
dc.description.sponsorship
FONDAP program
15150012
US Office of Naval Research-Global (ONR-G)
N62909-16-1-2003
Millennium Institute
P09-015-F
FONDEF
ID16I10223
D11E1007
US Air Force Office of Scientific Research
FA9550-16-1-0384
CONICYT-Brazil
441921/2016-7
ALS Therapy Alliance
2014-F-059
Muscular Dystrophy Association
382453
Michael J Fox Foundation for Parkinsons Research - Target Validation grant
9277
FONDECYT
1140549
11150579
3170622
Office of the Assistant Secretary of Defense for Health Affairs through the ALSRP Therapeutic Idea Award
W81XWH-16-1-0112
ALS Association
17-PDF-362